These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 8007709)
1. Heterogeneity of ductal carcinoma in situ of the breast. Lagios MD J Cell Biochem Suppl; 1993; 17G():49-52. PubMed ID: 8007709 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of surrogate endpoint biomarkers for ductal carcinoma in situ. Lagios MD J Cell Biochem Suppl; 1994; 19():186-8. PubMed ID: 7823590 [TBL] [Abstract][Full Text] [Related]
3. Ductal carcinoma in situ. The success of breast conservation therapy: a shared experience of two single institutional nonrandomized prospective studies. Lagios MD; Silverstein MJ Surg Oncol Clin N Am; 1997 Apr; 6(2):385-92. PubMed ID: 9115503 [TBL] [Abstract][Full Text] [Related]
4. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. Ottesen GL APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968 [TBL] [Abstract][Full Text] [Related]
5. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650 [TBL] [Abstract][Full Text] [Related]
6. Ductal carcinoma in situ of the breast: correlation of pathologic and mammographic features with extent of disease. Coombs JH; Hubbard E; Hudson K; Wunderlich C; VanMeter S; Bell JL; Gwin JL Am Surg; 1997 Dec; 63(12):1079-83. PubMed ID: 9393256 [TBL] [Abstract][Full Text] [Related]
7. Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience. Padmore RF; Fowble B; Hoffman J; Rosser C; Hanlon A; Patchefsky AS Cancer; 2000 Mar; 88(6):1403-9. PubMed ID: 10717623 [TBL] [Abstract][Full Text] [Related]
8. Optimal management of ductal carcinoma in situ of the breast. Sakorafas GH; Farley DR Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563 [TBL] [Abstract][Full Text] [Related]
9. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Boyages J; Delaney G; Taylor R Cancer; 1999 Feb; 85(3):616-28. PubMed ID: 10091735 [TBL] [Abstract][Full Text] [Related]
11. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525 [TBL] [Abstract][Full Text] [Related]
12. Value of sentinel lymph node biopsy in breast ductal carcinoma in situ upstaged to invasive carcinoma. Sakr R; Antoine M; Barranger E; Dubernard G; Salem C; Daraï E; Uzan S Breast J; 2008; 14(1):55-60. PubMed ID: 18186866 [TBL] [Abstract][Full Text] [Related]
13. BI-RADS MRI enhancement characteristics of ductal carcinoma in situ. Rosen EL; Smith-Foley SA; DeMartini WB; Eby PR; Peacock S; Lehman CD Breast J; 2007; 13(6):545-50. PubMed ID: 17983393 [TBL] [Abstract][Full Text] [Related]
14. Cytologic features of ductal carcinoma in situ in fine-needle aspiration of the breast mirror the histopathologic growth pattern heterogeneity and grading. Sauer T; Lømo J; Garred O; Naess O Cancer; 2005 Feb; 105(1):21-7. PubMed ID: 15593325 [TBL] [Abstract][Full Text] [Related]
15. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Sanders ME; Schuyler PA; Dupont WD; Page DL Cancer; 2005 Jun; 103(12):2481-4. PubMed ID: 15884091 [TBL] [Abstract][Full Text] [Related]
16. Correlation between type and grade of ductal carcinoma in situ and concomitant invasive ductal carcinoma of the breast. Rudnicka L; Stachura J Pol J Pathol; 2000; 51(3):137-43. PubMed ID: 11247396 [TBL] [Abstract][Full Text] [Related]
17. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives. Sakorafas GH; Tsiotou AG Cancer Treat Rev; 2000 Apr; 26(2):103-25. PubMed ID: 10772968 [TBL] [Abstract][Full Text] [Related]
18. Is there an indication for sentinel node biopsy in patients with ductal carcinoma in situ of the breast? A review. van Deurzen CH; Hobbelink MG; van Hillegersberg R; van Diest PJ Eur J Cancer; 2007 Apr; 43(6):993-1001. PubMed ID: 17300928 [TBL] [Abstract][Full Text] [Related]
19. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation. Solin LJ; McCormick B; Recht A; Haffty BG; Taylor ME; Kuske RR; Bornstein BA; McNeese M; Schultz DJ; Fowble BL; Barrett W; Yeh IT; Kurtz JM; Amalric R; Fourquet A Cancer J Sci Am; 1996; 2(3):158-65. PubMed ID: 9166516 [TBL] [Abstract][Full Text] [Related]
20. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. de Roos MA; de Bock GH; de Vries J; van der Vegt B; Wesseling J J Surg Res; 2007 Jun; 140(1):109-14. PubMed ID: 17291532 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]